tiero/iStock via Getty Images The stock of Credo Technology Group ( CRDO ) has been soaring over the last few weeks as AI spending remains on track and as the market rebounds from Iran war shocks. The company also announced after the close Monday that it would be acquiring DustPhotonics, a maker of silicon photonics, which are increasingly gaining importance in the data center. I think CRDO is jus...
tiero/iStock via Getty Images The stock of Credo Technology Group ( CRDO ) has been soaring over the last few weeks as AI spending remains on track and as the market rebounds from Iran war shocks. The company also announced after the close Monday that it would be acquiring DustPhotonics, a maker of silicon photonics, which are increasingly gaining importance in the data center. I think CRDO is just getting started and will continue to rise on the back of this positive upward momentum. Data by YCharts In my last piece on CRDO back in February, I discussed the company's upcoming catalysts and cheap valuation and rated it a Strong Buy. The stock has since risen by 65%, while the S&P 500 ( SPY ) was relatively flat. This appears to have been a well-timed call indeed! The reasons for the stock's recent blastoff have been varied, but the overall drive is likely that data center spending has remained strong and on track despite some macroeconomic headwinds and that market fears over Credo's place in the next era of AI infrastructure have been allayed. In this article, I'd like to provide some insight into what the company actually does and why the stock is now taking off. It's a bit hard to pinpoint a good thematic starting point for Credo to explain where it started and where it's going next, but I suppose a chronological timeline would do nicely, so let's start there. If you want to skip Credo's technological story, you can skip to the section titled "The Copper Wall." Humble Beginnings The year is 2008—AI is still colloquially known as the villain behind Skynet in the Terminator movies, and no one outside of the most hardcore researchers has even heard of an "LLM." Credo opens its doors, offering licenses on its SerDes (serializer/deserializer) IP, which provides low-power network connectivity. A few years later, around 2015, the company also begins licensing its designs for a digital signal processor ("DSP"), which is used by larger manufacturers and integrated into th...
Shares of Insteel Industries (NYSE: IIIN) fell nearly 20% by 2 p.m. today after disappointing second-quarter earnings. The results reflect broader trends likely to emerge during this earnings season. Insteel manufactures and markets steel wire reinforcing products for application in reinforced concrete structures, principally in non-residential construction. It's the kind of business with relative...
Shares of Insteel Industries (NYSE: IIIN) fell nearly 20% by 2 p.m. today after disappointing second-quarter earnings. The results reflect broader trends likely to emerge during this earnings season. Insteel manufactures and markets steel wire reinforcing products for application in reinforced concrete structures, principally in non-residential construction. It's the kind of business with relatively high fixed costs and exposure to raw material costs, particularly steel . As such, a combination of tariff costs, rising energy costs, and higher freight costs is pressuring its costs. The good news is that the company is raising prices in response (a 16.2% increase in average selling prices in the quarter), and, as CEO H.O. Woltz III noted in the earnings release, "we are comfortable with our market position that includes minimal direct import competition." Woltz, no doubt, feels that way because Insteel sells heavy products that are difficult for foreign competitors to ship into the country at competitive prices. Continue reading
During the trailing five years, shares of social media company Snap (NYSE: SNAP) have endured a brutal drawdown. The stock has collapsed, falling about 90%. This steep decline comes as the Snapchat parent company seems to struggle to consistently grow revenue and achieve meaningful double-digit growth, and to achieve meaningful profitability in the face of intense competition from deep-pocketed te...
During the trailing five years, shares of social media company Snap (NYSE: SNAP) have endured a brutal drawdown. The stock has collapsed, falling about 90%. This steep decline comes as the Snapchat parent company seems to struggle to consistently grow revenue and achieve meaningful double-digit growth, and to achieve meaningful profitability in the face of intense competition from deep-pocketed tech giants like Meta Platforms (NASDAQ: META) . Adding to the narrative, Snap just announced a fresh round of layoffs this week. While cost-cutting measures are often cheered by investors as a step toward profitability, the move also highlights the ongoing challenges facing the business. Continue reading
Earnings Call Insights: KeyCorp (KEY) Q1 2026 Management View “Our strong first quarter performance demonstrates disciplined execution and significant momentum as we continue to deliver on our commitments,” said (Chairman, President & CEO Christopher Gorman), highlighting “earnings of $0.44 per share,” “return on tangible common equity exceeded 13%,” and that the company remains on track for “15%-...
Earnings Call Insights: KeyCorp (KEY) Q1 2026 Management View “Our strong first quarter performance demonstrates disciplined execution and significant momentum as we continue to deliver on our commitments,” said (Chairman, President & CEO Christopher Gorman), highlighting “earnings of $0.44 per share,” “return on tangible common equity exceeded 13%,” and that the company remains on track for “15%-plus return on tangible common equity by year-end 2027.” (CEO Gorman) tied profitability to balance-sheet trends, saying “net interest margin expanded 5 basis points sequentially to 2.87%” and the bank remains “on track to exceed 3% net interest margin by year-end,” while noting “commercial loan growth was strong and broad-based… increasing $3.3 billion or 4% sequentially.” (CEO Gorman) emphasized capital return and regulation tailwinds: “we… repurchased nearly $400 million of common stock,” and “subject to market conditions, we expect to buy back at least $1.3 billion of our shares in 2026, up from the $1.2 billion we previously communicated,” while adding the revised Basel proposal could provide “a 100-plus basis point benefit to our marked CET1 ratio.” (Chief Financial Officer Clark Khayat) summarized operating leverage and credit: “Revenue was up 10% year-over-year, while expenses increased by 4%,” and “loan loss provision of $106 million included… net charge-offs… and a reserve build of $5 million,” with the build reflecting “additional qualitative reserves to account for the macro uncertainty.” (CFO Khayat) provided expanded exposure detail on private credit and NDFI, stating, “we estimate approximately $10.9 billion of outstandings as of March 31,” and adding, “through the first quarter, all of our facilities are performing as structured and required.” (CEO Gorman) announced a leadership scope change: “Clark has assumed an expanded role to lead our technology and operations organization, in addition to his role as CFO.” Outlook (CFO Khayat) raised 2026 net interest i...
The journey from a laboratory hypothesis to a pharmacy shelf is one of the most grueling marathons in modern industry, typically spanning 10 to 15 years and billions of dollars in investment. Progress is often stymied not just by the inherent mysteries of biology, but by the "fragmented and difficult to scale" workflows that force researchers to manually pivot between the actual experimental desig...
The journey from a laboratory hypothesis to a pharmacy shelf is one of the most grueling marathons in modern industry, typically spanning 10 to 15 years and billions of dollars in investment. Progress is often stymied not just by the inherent mysteries of biology, but by the "fragmented and difficult to scale" workflows that force researchers to manually pivot between the actual experimental design equipment, software, and databases. But OpenAI is releasing a new specialized model GPT-Rosalind specifically to speed up this process and make it more efficient, easier, and ideally, more productive. Named after the pioneering chemist Rosalind Franklin, whose work was vital to the discovery of DNA’s structure (and was often overlooked for her male colleagues James Watson and Francis Crick), this new frontier reasoning model is purpose-built to act as a specialized intelligence layer for life sciences research. By shifting AI’s role from a general-purpose assistant to a domain-specific "reasoning" partner, OpenAI is signaling a long-term commitment to biological and chemical discovery. What GPT-Rosalind offers GPT-Rosalind isn't just about faster text generation; it is designed to synthesize evidence, generate biological hypotheses, and plan experiments—tasks that have traditionally required years of expert human synthesis. At its core, GPT-Rosalind is the first in a new series of models optimized for scientific workflows. While previous iterations of GPT excelled at general language tasks, this model is fine-tuned for deeper understanding across genomics, protein engineering, and chemistry. To validate its capabilities, OpenAI tested the model against several industry benchmarks. On BixBench, a metric for real-world bioinformatics and data analysis, GPT-Rosalind achieved leading performance among models with published scores. In more granular testing via LABBench2, the model outperformed GPT-5.4 on six out of eleven tasks, with the most significant gains appearing in Clo...
After a jury found that Live Nation-Ticketmaster violated antitrust law on several counts, the company warns in a blog post that the verdict "is not the last word on this matter." The company plans to renew a motion for the judge to issue a ruling against the states, claiming that they did not prove their case as a matter of law. It also awaits the court's decision on a separate motion to strike t...
After a jury found that Live Nation-Ticketmaster violated antitrust law on several counts, the company warns in a blog post that the verdict "is not the last word on this matter." The company plans to renew a motion for the judge to issue a ruling against the states, claiming that they did not prove their case as a matter of law. It also awaits the court's decision on a separate motion to strike the testimony of one of the states' expert witness, whose analysis they say helped inform the jury's damages award. The jury found that Ticketmaster overcharged consumers $1.72 per ticket. "Of course, Live Nation can and will appeal any unfavorable … Read the full story at The Verge.
Kirsten Vangsness, actress and writer, joins Scarlet Fu on "Bloomberg Markets." More than 3,000 Hollywood actors, directors and screenwriters have penned a letter opposing the $110 billion takeover of Warner Bros. Discovery by Paramount Skydance Corp., citing concerns about job losses and higher costs with fewer choices for consumers. (Source: Bloomberg)
Kirsten Vangsness, actress and writer, joins Scarlet Fu on "Bloomberg Markets." More than 3,000 Hollywood actors, directors and screenwriters have penned a letter opposing the $110 billion takeover of Warner Bros. Discovery by Paramount Skydance Corp., citing concerns about job losses and higher costs with fewer choices for consumers. (Source: Bloomberg)
OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way for more scientific breakthroughs. The ChatGPT maker said Thursday that the model, GPT-Rosalind, is intended for life sciences research, such as helping glean insights from large volumes of data and ...
OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way for more scientific breakthroughs. The ChatGPT maker said Thursday that the model, GPT-Rosalind, is intended for life sciences research, such as helping glean insights from large volumes of data and turning scientific studies into health-care applications for patients. The model will be available initially as a research preview to some of the company’s business customers, OpenAI said. The initial users include drugmaker Amgen Inc. , vaccine maker Moderna Inc. and the Allen Institute, a bioscience research nonprofit. OpenAI, Anthropic PBC and Alphabet Inc.’s Google have increasingly focused on scientific and health-care applications for AI, ranging from using the technology to help guide research on new drugs to having it review personal medical data . In 2024, two Google DeepMind scientists shared the Nobel Prize in chemistry for AlphaFold, an AI system that predicts protein structures. The technology is generally seen as nascent but promising, and some drugs discovered with the help of AI have been involved in early clinical trials . Joy Jiao, who leads OpenAI’s life science research, said the company hopes the model can act as a research partner for businesses using it, particularly for biology work that is increasingly reliant on computers. Though OpenAI doesn’t yet believe AI can be used on its own to come up with new treatments for diseases, “we do think there’s a real opportunity to help researchers move faster through some of the most complex and time-intensive parts of the scientific process,” she said in a briefing with reporters. OpenAI and rival Anthropic have been racing to develop more advanced AI models that can take on a wider range of tasks, including coding, science and cybersecurity, with the hope of convincing more businesses the technology will save...
Whether investors are fending off choppy markets or grappling with fears of stagflation, stocks that offer attractive but sustainable yields can help protect their portfolios, Bank of America found. The S & P 500 touched a new all-time high on Thursday after President Donald Trump announced that Israel and Lebanon have agreed to a10-day ceasefire . Oil was still positive on the day, with Brent cru...
Whether investors are fending off choppy markets or grappling with fears of stagflation, stocks that offer attractive but sustainable yields can help protect their portfolios, Bank of America found. The S & P 500 touched a new all-time high on Thursday after President Donald Trump announced that Israel and Lebanon have agreed to a10-day ceasefire . Oil was still positive on the day, with Brent crude futures up more than 4% and ahead more than 37% since the start of the U.S.-Israel war with Iran in late February. "The war with Iran poses risk of a stagflation shock," wrote Bank of America's head of U.S. equity strategy and U.S. quantitative strategy Savita Subramanian in a Thursday report. "Our analysis of factor performance during periods of below-trend growth and above trend inflation since 1987 indicates that Quality and Cash Deployment groups fared best." "If we are returning to a total return world in which the contribution of dividends to total market returns could be higher than during the zero interest rates period, we advise investors to seek out companies with above-market but not stretched dividend yields," she added. With the S & P 500 offering a meager dividend yield of about 1.1%, "above-market" dividend yields are a more achievable bogey. To that end, Bank of America screened the Russell 1000, searching for names in the second quintile for trailing dividend yield. Companies in this cohort are less likely to be distressed compared to their peers in the first quintile – that is, firms offering the highest dividend yield. Companies with the highest dividend yields can prove riskier for investors. First, those high yields may mean that the stock price is on a sharp, downward trajectory. Second, the companies with the highest dividend yield may be more inclined to chop their payments if they are under financial pressure. Here are a few stocks that turned up in Bank of America's screen. PepsiCo is a dividend aristocrat, having announced a 4% dividend hike in...
Welcome back to Soundbite. It’s that time again – Edison Research is putting out its quarterly top podcast ranker, and despite speculation online that Ben Shapiro has lost relevancy in the great MAGA podcast schism, Edison’s work suggests he’s back toward the top. We’ll dig in. If you appreciate this kind of work, please support it and subscribe . Reach me through email . Up first, here’s what I’m...
Welcome back to Soundbite. It’s that time again – Edison Research is putting out its quarterly top podcast ranker, and despite speculation online that Ben Shapiro has lost relevancy in the great MAGA podcast schism, Edison’s work suggests he’s back toward the top. We’ll dig in. If you appreciate this kind of work, please support it and subscribe . Reach me through email . Up first, here’s what I’m reading and writing this week. Live Nation Entertainment Inc. is a monopoly , according to the New York jury that ruled on the major antitrust trial on Wednesday. My colleagues at the court house talked to the jurors. The evidence that partially swayed them? They didn’t like the tone of the emails sent by Live Nation executives. Now it’s up to the judge to determine whether the company can keep Ticketmaster or what other remedies must be followed. Wired claims the Geese is a “psyop” because the band (or its label) hired a marketing firm to flood the internet with clips on various unmarked-but-company-owned TikTok accounts hyping their music. People have proceeded to freak out about whether this is beyond the pale or just the reality of marketing these days. Personally, I think there is plenty of content that’s significantly worse for society already being astroturfed and clipped ad infinitum, which people should be way more worried about. Plus, I don’t think this music would have taken off in the way that it did, regardless of the clipping, if it wasn’t good The Daily Wire fights for its life (and attention) Only a year ago, the conservative podcast world was jubilant. Commentators ranging from pundits like Megyn Kelly to comedians like Joe Rogan had endorsed President Donald Trump, and he’d won the White House. On top of that, the election was partially chalked up to their podcast efforts. The world was theirs . “I feel euphoric and also kind of crazy,” Kelly wrote on a blog post describing her time in Washington for the inauguration. Today, things are less harmonious amo...
Sundry Photography/iStock Editorial via Getty Images A new earnings season has arrived. If ASML’s earnings is any guide, be prepared to hear another quarter of “demand is outstripping supply” from all the players in the semi value chain. ASML’s ( ASML ) CEO, Christophe Fouquet, started his prepared remarks with the following, which set the tone: “…for the foreseeable future, demand will continue t...
Sundry Photography/iStock Editorial via Getty Images A new earnings season has arrived. If ASML’s earnings is any guide, be prepared to hear another quarter of “demand is outstripping supply” from all the players in the semi value chain. ASML’s ( ASML ) CEO, Christophe Fouquet, started his prepared remarks with the following, which set the tone: “…for the foreseeable future, demand will continue to outpace supply. This creates constraints across end markets from AI to mobile and PCs, which is driving our customers to aggressively add capacity.” The last question on the call was about whether ASML may become the bottleneck for supply to get closer to demand. Fouquet does not think that is the case: I know the question of bottleneck comes back very often. I think we don’t feel at all that we are the bottleneck today. We’re very closely working with our customer. And again, we have many, many, many tools in our hands to make sure we keep it this way. During the call, ASML management explained how much they are expanding capacity to meet the growing demand (emphasis mine): last year, we had 44 tools. If you are just looking at 80 tools, we say at least 80, but if you just look at 80 tools, those 80 tools give you double the wafer per hour capacity that we would have shipped in 2025. And on top of that, we’re helping customers upgrade their installed base… we’re really working hand in glove with the customers to look at what is your capacity need, what’s the easiest way and also the most economical way for you to get to the productivity that you need. And we’re executing on all fronts on availability, on productivity, on unit numbers, capacity and then upgrading the installed base. I find it quite remarkable how quickly ASML was able to expand the capacity despite having a maze-like supply chain. For context, ASML had 5,150 suppliers in 2024; therefore, ramping up capacity means ASML needs most of these suppliers to also step up their game simultaneously to meet ASML’s w...
If you’re struggling to get a full night of rest, a good pair of sleep earbuds can help you tune out unwanted distractions. The Ozlo Sleepbuds are one such option, and they’re currently available for $249 ($100 off) in the run-up to Mother’s Day at Amazon and Ozlo’s online storefront , which is easily the lowest price we’ve seen. Ozlo Sleepbuds Where to Buy: $349 $249 at Amazon $349 $249 at Ozlo $...
If you’re struggling to get a full night of rest, a good pair of sleep earbuds can help you tune out unwanted distractions. The Ozlo Sleepbuds are one such option, and they’re currently available for $249 ($100 off) in the run-up to Mother’s Day at Amazon and Ozlo’s online storefront , which is easily the lowest price we’ve seen. Ozlo Sleepbuds Where to Buy: $349 $249 at Amazon $349 $249 at Ozlo $349 $259.99 at Best Buy Made by former Bose engineers , Ozlo’s Sleepbuds are extremely similar to Bose’s discontinued Sleepbuds. They work well as a white noise machine and helped our reviewer, Victoria Song, get better sleep during her testing. The biggest upgrade over the Bose Sleepbuds II is that you’re no longer limited to a small library of white noise sounds. The Ozlo buds let you play your own audio, then switch back to white noise once you’ve fallen asleep. In our experience, that feature is a bit hit-or-miss, but when it does work, it’s helpful. In November, Ozlo added a host of sleep tracking features to both the earbuds and their charging case as part of a beta, allowing you to track your sleeping habits and the factors that might disrupt your cycle (we’ve yet to test them). Otherwise, the Ozlo Sleepbuds are largely similar to the last-gen Bose. They’re lightweight, comfortable for side sleepers, and stay put overnight. Battery life still lasts up to 10 hours, which is enough for a full night, and you can set private alarms that won’t disturb anybody else. They’re not quite as advanced as Soundcore’s newer Sleep A30 earbuds — which offer active noise cancellation and an adaptive snore masking feature — but if you just want a comfortable pair of earbuds built specifically to help you sleep, they do the job quite nicely.